Literature DB >> 18300073

Neurovirulent factor ICP34.5 uniquely expressed in the herpes simplex virus type 1 Delta gamma 1 34.5 mutant 1716.

Holly A Holman1, Alasdair R MacLean.   

Abstract

The herpes simplex virus type 1 (HSV-1) diploid gene gamma(1)34.5 encodes a neurovirulent factor, infected cell protein 34.5 (ICP34.5). The promoter to gamma(1)34.5 is located within the HSV-1 genome where there are repeated sequences. This region of the genome also contains important overlapping transcripts involved with the virus's ability to establish lytic and latent infections and reactivation. These transcripts include the latency-associated transcripts and regulator proteins ICP0 and ICP4. This study aimed to separate ICP34.5 from these overlapping transcripts and test if its expression from a single gene could restore wild-type HSV-1 strain 17+ virulence. To address these aims, different recombinant viruses were constructed using the Delta gamma(1)34.5 mutant 1716. Immunoblots probed with different ICP34.5 antisera demonstrated that one of the newly generated recombinant viruses, 1622, overexpresses ICP34.5 relative to a panel of wild-type viruses. Interestingly, the overexpression of ICP34.5 does not yield a more virulent virus. The onset of ICP34.5 expression from 1622-infected cells in vitro matched that of 17+, and its expression restored the function of maintaining protein synthesis in human neuroblastoma cells. Replication of 1622, however, was only partially restored to 17+ levels in vivo. Additionally, plaque morphology from 1622-infected cells indicates there is an additional defect. The authors report that the mutant virus 1622 can express ICP34.5 from a single gamma(1)34.5 gene and restore most (but not all) wild-type function. These findings are discussed with respect to the use of the gamma(1)34.5 deleted mutant, 1716, in oncolytic viral vector therapies and future studies for ICP34.5.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18300073     DOI: 10.1080/13550280701769999

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  33 in total

1.  Quantitative analysis of herpes simplex virus reactivation in vivo demonstrates that reactivation in the nervous system is not inhibited at early times postinoculation.

Authors:  N M Sawtell
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

2.  Neurovirulence factor.

Authors:  D J McGeoch; B C Barnett
Journal:  Nature       Date:  1991-10-17       Impact factor: 49.962

Review 3.  Regulation of the interferon-induced PKR: can viruses cope?

Authors:  M G Katze
Journal:  Trends Microbiol       Date:  1995-02       Impact factor: 17.079

4.  A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function.

Authors:  I Mohr; Y Gluzman
Journal:  EMBO J       Date:  1996-09-02       Impact factor: 11.598

5.  Recombinant vaccinia virus K3L gene product prevents activation of double-stranded RNA-dependent, initiation factor 2 alpha-specific protein kinase.

Authors:  K Carroll; O Elroy-Stein; B Moss; R Jagus
Journal:  J Biol Chem       Date:  1993-06-15       Impact factor: 5.157

6.  The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase.

Authors:  B He; M Gross; B Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-04       Impact factor: 11.205

7.  Strain-dependent structural variants of herpes simplex virus type 1 ICP34.5 determine viral plaque size, efficiency of glycoprotein processing, and viral release and neuroinvasive disease potential.

Authors:  Hanwen Mao; Ken S Rosenthal
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

8.  Histopathological responses in the CNS following inoculation with a non-neurovirulent mutant (1716) of herpes simplex virus type 1 (HSV 1): relevance for gene and cancer therapy.

Authors:  E A McKie; S M Brown; A R MacLean; D I Graham
Journal:  Neuropathol Appl Neurobiol       Date:  1998-10       Impact factor: 8.090

9.  Characterization of the herpes simplex virus type 1 strain 17+ neurovirulence gene RL1 and its expression in a bacterial system.

Authors:  E A McKie; R G Hope; S M Brown; A R MacLean
Journal:  J Gen Virol       Date:  1994-04       Impact factor: 3.891

10.  The herpes simplex virus type 1 strain 17 open reading frame RL1 encodes a polypeptide of apparent M(r) 37K equivalent to ICP34.5 of herpes simplex virus type 1 strain F.

Authors:  E M McKay; B McVey; H S Marsden; S M Brown; A R MacLean
Journal:  J Gen Virol       Date:  1993-11       Impact factor: 3.891

View more
  5 in total

1.  In vitro detection of cholangiocarcinoma cells using a fluorescent protein-expressing oncolytic herpes virus.

Authors:  R J S Coelen; M J de Keijzer; R Weijer; V V Loukachov; J K Wiggers; F P J Mul; A C W A van Wijk; Y Fong; M Heger; T M van Gulik
Journal:  Cancer Gene Ther       Date:  2017-04-14       Impact factor: 5.987

2.  Herpes simplex virus 2 expresses a novel form of ICP34.5, a major viral neurovirulence factor, through regulated alternative splicing.

Authors:  Shuang Tang; Nini Guo; Amita Patel; Philip R Krause
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

3.  Up to four distinct polypeptides are produced from the γ34.5 open reading frame of herpes simplex virus 2.

Authors:  Maria Korom; Katie L Davis; Lynda A Morrison
Journal:  J Virol       Date:  2014-07-16       Impact factor: 5.103

4.  Novel less-abundant viral microRNAs encoded by herpes simplex virus 2 latency-associated transcript and their roles in regulating ICP34.5 and ICP0 mRNAs.

Authors:  Shuang Tang; Amita Patel; Philip R Krause
Journal:  J Virol       Date:  2008-11-19       Impact factor: 5.103

Review 5.  Oncolytic Viruses as a Platform for the Treatment of Malignant Brain Tumors.

Authors:  Jana de Sostoa; Valérie Dutoit; Denis Migliorini
Journal:  Int J Mol Sci       Date:  2020-10-09       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.